A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

NCT03720678 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

GastroEsophageal Cancer
Colorectal Cancer

Interventions

DRUG: etrumadenant
DRUG: mFOLFOX

Sponsor

Arcus Biosciences, Inc.